Oral gliadin‐protected superoxide dismutase in addition to phototherapy for treating non‐segmental vitiligo: A 24‐week prospective randomized placebo‐controlled study

Background Despite a solid rationale, the usefulness of antioxidants in treating vitiligo has not been clearly demonstrated. Combining superoxide dismutase (SOD) with a wheat gliadin biopolymer protects it during the passage through the gastrointestinal tract. Objective To evaluate the efficacy of g...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology 2021-08, Vol.35 (8), p.1725-1729
Main Authors: Fontas, E., Montaudié, H., Passeron, T.
Format: Article
Language:English
Subjects:
Original
Pigmentary Diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4151-166d4476486f5eb86c5ff9f02fe9b54adac50744645b10bf6847aedef8315cff3
cites cdi_FETCH-LOGICAL-c4151-166d4476486f5eb86c5ff9f02fe9b54adac50744645b10bf6847aedef8315cff3
container_end_page 1729
container_issue 8
container_start_page 1725
container_title Journal of the European Academy of Dermatology and Venereology
container_volume 35
creator Fontas, E.
Montaudié, H.
Passeron, T.
description Background Despite a solid rationale, the usefulness of antioxidants in treating vitiligo has not been clearly demonstrated. Combining superoxide dismutase (SOD) with a wheat gliadin biopolymer protects it during the passage through the gastrointestinal tract. Objective To evaluate the efficacy of gliadin‐protected SOD (GP‐SOD), associated with narrowband ultraviolet B(NB‐UVB), for treating vitiligo. Methods We conducted a 24‐week monocentric interventional prospective randomized placebo‐controlled trial in the tertiary center for vitiligo care in the department of Dermatology of Nice University hospital, Nice, France. Subjects with non‐segmental vitiligo affecting more than 5% of the total body surface were included. The subjects received gliadin‐protected SOD (GP‐SOD; 1 g/day for 12 weeks followed by 0.5 g/day for 12 weeks) or placebo in combination with twice‐weekly sessions of NB‐UVB. The primary endpoint was the total repigmentation rate at 24 weeks, compared with baseline, as assessed by investigator‐assessed Vitiligo Extent Score (VES) on standardized pictures. Results A total of 50 patients were included. After 24 weeks, a greater improvement in VES was observed in the GP‐SOD group (19.85%; SE 4.63, P 
doi_str_mv 10.1111/jdv.17331
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8360035</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2520853479</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4151-166d4476486f5eb86c5ff9f02fe9b54adac50744645b10bf6847aedef8315cff3</originalsourceid><addsrcrecordid>eNp1kc1u1TAQhSMEopfCghdAXtJFWjv-ScICqSr_qtQNsLWceJzrktjBdm65XfUReBIeiifBl1sqWDCbWcznc8ZziuIpwcck18ml3hyTmlJyr1gRJpqS4obeL1a4rUTZtrw9KB7FeIkxJoQ3D4sDSltKWoxXxY-LoEY0jFZp637efJ-DT9An0CguMwT_zWpA2sZpSSoCsg4prW2y3qHk0bz2yac1BDVvkfEBpQAqWTcg53dqEYYJXMoOm_xmtIN_gU5RxfLoCuALym5xznZ2Aygop_1kr7P1PKoeOp-p3rsU_Dju9kmL3j4uHhg1Rnhy2w-LT29efzx7V55fvH1_dnpe9oxwUhIhNGO1YI0wHLpG9NyY1uDKQNtxprTqOa4ZE4x3BHdGNKxWoME0lPDeGHpYvNzrzks3ge7zJ_Kd5BzspMJWemXlvxNn13LwG9lQgTHlWeD5rUDwXxeISU429jCOyoFfoqx4hRtOWd1m9GiP9vkaMYC5syFY7vKVOV_5O9_MPvt7rzvyT6AZONkDV3aE7f-V5IdXn_eSvwDAV7oz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2520853479</pqid></control><display><type>article</type><title>Oral gliadin‐protected superoxide dismutase in addition to phototherapy for treating non‐segmental vitiligo: A 24‐week prospective randomized placebo‐controlled study</title><source>Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)</source><creator>Fontas, E. ; Montaudié, H. ; Passeron, T.</creator><creatorcontrib>Fontas, E. ; Montaudié, H. ; Passeron, T.</creatorcontrib><description>Background Despite a solid rationale, the usefulness of antioxidants in treating vitiligo has not been clearly demonstrated. Combining superoxide dismutase (SOD) with a wheat gliadin biopolymer protects it during the passage through the gastrointestinal tract. Objective To evaluate the efficacy of gliadin‐protected SOD (GP‐SOD), associated with narrowband ultraviolet B(NB‐UVB), for treating vitiligo. Methods We conducted a 24‐week monocentric interventional prospective randomized placebo‐controlled trial in the tertiary center for vitiligo care in the department of Dermatology of Nice University hospital, Nice, France. Subjects with non‐segmental vitiligo affecting more than 5% of the total body surface were included. The subjects received gliadin‐protected SOD (GP‐SOD; 1 g/day for 12 weeks followed by 0.5 g/day for 12 weeks) or placebo in combination with twice‐weekly sessions of NB‐UVB. The primary endpoint was the total repigmentation rate at 24 weeks, compared with baseline, as assessed by investigator‐assessed Vitiligo Extent Score (VES) on standardized pictures. Results A total of 50 patients were included. After 24 weeks, a greater improvement in VES was observed in the GP‐SOD group (19.85%; SE 4.63, P &lt; 0.0001) compared with the placebo group (8.83%; SE 4.72, P = 0.0676). Tolerance was good in both groups. No related side‐effect was reported. Conclusions The use of GP‐SOD appears to be a useful add‐on to phototherapy in the treatment of vitiligo patients.</description><identifier>ISSN: 0926-9959</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/jdv.17331</identifier><identifier>PMID: 33931900</identifier><language>eng</language><publisher>England: John Wiley and Sons Inc</publisher><subject>Original ; Pigmentary Diseases</subject><ispartof>Journal of the European Academy of Dermatology and Venereology, 2021-08, Vol.35 (8), p.1725-1729</ispartof><rights>2021 The Authors. published by John Wiley &amp; Sons Ltd on behalf of European Academy of Dermatology and Venereology</rights><rights>2021 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Dermatology and Venereology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4151-166d4476486f5eb86c5ff9f02fe9b54adac50744645b10bf6847aedef8315cff3</citedby><cites>FETCH-LOGICAL-c4151-166d4476486f5eb86c5ff9f02fe9b54adac50744645b10bf6847aedef8315cff3</cites><orcidid>0000-0002-0797-6570 ; 0000-0002-1849-9626 ; 0000-0002-0528-4829</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33931900$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fontas, E.</creatorcontrib><creatorcontrib>Montaudié, H.</creatorcontrib><creatorcontrib>Passeron, T.</creatorcontrib><title>Oral gliadin‐protected superoxide dismutase in addition to phototherapy for treating non‐segmental vitiligo: A 24‐week prospective randomized placebo‐controlled study</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J Eur Acad Dermatol Venereol</addtitle><description>Background Despite a solid rationale, the usefulness of antioxidants in treating vitiligo has not been clearly demonstrated. Combining superoxide dismutase (SOD) with a wheat gliadin biopolymer protects it during the passage through the gastrointestinal tract. Objective To evaluate the efficacy of gliadin‐protected SOD (GP‐SOD), associated with narrowband ultraviolet B(NB‐UVB), for treating vitiligo. Methods We conducted a 24‐week monocentric interventional prospective randomized placebo‐controlled trial in the tertiary center for vitiligo care in the department of Dermatology of Nice University hospital, Nice, France. Subjects with non‐segmental vitiligo affecting more than 5% of the total body surface were included. The subjects received gliadin‐protected SOD (GP‐SOD; 1 g/day for 12 weeks followed by 0.5 g/day for 12 weeks) or placebo in combination with twice‐weekly sessions of NB‐UVB. The primary endpoint was the total repigmentation rate at 24 weeks, compared with baseline, as assessed by investigator‐assessed Vitiligo Extent Score (VES) on standardized pictures. Results A total of 50 patients were included. After 24 weeks, a greater improvement in VES was observed in the GP‐SOD group (19.85%; SE 4.63, P &lt; 0.0001) compared with the placebo group (8.83%; SE 4.72, P = 0.0676). Tolerance was good in both groups. No related side‐effect was reported. Conclusions The use of GP‐SOD appears to be a useful add‐on to phototherapy in the treatment of vitiligo patients.</description><subject>Original</subject><subject>Pigmentary Diseases</subject><issn>0926-9959</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kc1u1TAQhSMEopfCghdAXtJFWjv-ScICqSr_qtQNsLWceJzrktjBdm65XfUReBIeiifBl1sqWDCbWcznc8ZziuIpwcck18ml3hyTmlJyr1gRJpqS4obeL1a4rUTZtrw9KB7FeIkxJoQ3D4sDSltKWoxXxY-LoEY0jFZp637efJ-DT9An0CguMwT_zWpA2sZpSSoCsg4prW2y3qHk0bz2yac1BDVvkfEBpQAqWTcg53dqEYYJXMoOm_xmtIN_gU5RxfLoCuALym5xznZ2Aygop_1kr7P1PKoeOp-p3rsU_Dju9kmL3j4uHhg1Rnhy2w-LT29efzx7V55fvH1_dnpe9oxwUhIhNGO1YI0wHLpG9NyY1uDKQNtxprTqOa4ZE4x3BHdGNKxWoME0lPDeGHpYvNzrzks3ge7zJ_Kd5BzspMJWemXlvxNn13LwG9lQgTHlWeD5rUDwXxeISU429jCOyoFfoqx4hRtOWd1m9GiP9vkaMYC5syFY7vKVOV_5O9_MPvt7rzvyT6AZONkDV3aE7f-V5IdXn_eSvwDAV7oz</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Fontas, E.</creator><creator>Montaudié, H.</creator><creator>Passeron, T.</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0797-6570</orcidid><orcidid>https://orcid.org/0000-0002-1849-9626</orcidid><orcidid>https://orcid.org/0000-0002-0528-4829</orcidid></search><sort><creationdate>202108</creationdate><title>Oral gliadin‐protected superoxide dismutase in addition to phototherapy for treating non‐segmental vitiligo: A 24‐week prospective randomized placebo‐controlled study</title><author>Fontas, E. ; Montaudié, H. ; Passeron, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4151-166d4476486f5eb86c5ff9f02fe9b54adac50744645b10bf6847aedef8315cff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Original</topic><topic>Pigmentary Diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fontas, E.</creatorcontrib><creatorcontrib>Montaudié, H.</creatorcontrib><creatorcontrib>Passeron, T.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fontas, E.</au><au>Montaudié, H.</au><au>Passeron, T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral gliadin‐protected superoxide dismutase in addition to phototherapy for treating non‐segmental vitiligo: A 24‐week prospective randomized placebo‐controlled study</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2021-08</date><risdate>2021</risdate><volume>35</volume><issue>8</issue><spage>1725</spage><epage>1729</epage><pages>1725-1729</pages><issn>0926-9959</issn><eissn>1468-3083</eissn><abstract>Background Despite a solid rationale, the usefulness of antioxidants in treating vitiligo has not been clearly demonstrated. Combining superoxide dismutase (SOD) with a wheat gliadin biopolymer protects it during the passage through the gastrointestinal tract. Objective To evaluate the efficacy of gliadin‐protected SOD (GP‐SOD), associated with narrowband ultraviolet B(NB‐UVB), for treating vitiligo. Methods We conducted a 24‐week monocentric interventional prospective randomized placebo‐controlled trial in the tertiary center for vitiligo care in the department of Dermatology of Nice University hospital, Nice, France. Subjects with non‐segmental vitiligo affecting more than 5% of the total body surface were included. The subjects received gliadin‐protected SOD (GP‐SOD; 1 g/day for 12 weeks followed by 0.5 g/day for 12 weeks) or placebo in combination with twice‐weekly sessions of NB‐UVB. The primary endpoint was the total repigmentation rate at 24 weeks, compared with baseline, as assessed by investigator‐assessed Vitiligo Extent Score (VES) on standardized pictures. Results A total of 50 patients were included. After 24 weeks, a greater improvement in VES was observed in the GP‐SOD group (19.85%; SE 4.63, P &lt; 0.0001) compared with the placebo group (8.83%; SE 4.72, P = 0.0676). Tolerance was good in both groups. No related side‐effect was reported. Conclusions The use of GP‐SOD appears to be a useful add‐on to phototherapy in the treatment of vitiligo patients.</abstract><cop>England</cop><pub>John Wiley and Sons Inc</pub><pmid>33931900</pmid><doi>10.1111/jdv.17331</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-0797-6570</orcidid><orcidid>https://orcid.org/0000-0002-1849-9626</orcidid><orcidid>https://orcid.org/0000-0002-0528-4829</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0926-9959
ispartof Journal of the European Academy of Dermatology and Venereology, 2021-08, Vol.35 (8), p.1725-1729
issn 0926-9959
1468-3083
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8360035
source Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)
subjects Original
Pigmentary Diseases
title Oral gliadin‐protected superoxide dismutase in addition to phototherapy for treating non‐segmental vitiligo: A 24‐week prospective randomized placebo‐controlled study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A55%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20gliadin%E2%80%90protected%20superoxide%20dismutase%20in%20addition%20to%20phototherapy%20for%20treating%20non%E2%80%90segmental%20vitiligo:%20A%2024%E2%80%90week%20prospective%20randomized%20placebo%E2%80%90controlled%20study&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Fontas,%20E.&rft.date=2021-08&rft.volume=35&rft.issue=8&rft.spage=1725&rft.epage=1729&rft.pages=1725-1729&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/jdv.17331&rft_dat=%3Cproquest_pubme%3E2520853479%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4151-166d4476486f5eb86c5ff9f02fe9b54adac50744645b10bf6847aedef8315cff3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2520853479&rft_id=info:pmid/33931900&rfr_iscdi=true